Chemical Technology

Energy transition and decarbonization Pathways for the chemical industry

August 16, 2022

Energy transition
Like all industries, the chemical sector is under pressure to bring its operations and value chain on track toward a more sustainable and resilient energy future. In the medium and long term.

Spotlight

Zafgen, Inc.

Zafgen is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. The company has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and other rare and serious forms of obesity. Zafgen is well-capitalized and has assembled a team accomplished in bringing therapies to patients affected by metabolic disease.

OTHER WHITEPAPERS
news image

Transitioning Industrial Clusters towards Net Zero: National Policy Enablement for Industrial Decarbonization

whitePaper | November 11, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed.

Read More
news image

chemicals Evolution of a digital twin with an ethylene plant as an example

whitePaper | January 17, 2020

A digital twin of a process plant as an integrated concept covers three core points: The digital twin of the product, the digital twin of the production plant and the digital modeling of the performance of the product and production. The functional scope of a digital twin essentially depends on its purpose. In the process industry, this can be everything from the safety analysis, product simulation or the optimization of the production process, right up to economic benefit formulation.

Read More
news image

Petrochemical Industry ENSURING SAFETY AND UPTIME WITH SECURE PROCESS CONTROL NETWORKS

whitePaper | December 30, 2019

The industrial control systems for production facilities in eight countries from North America to Asia were being managed locally at each site, with no standardized components or corporate view. Reporting on the security status of these systems relied heavily on manual processes and often was not reliable. System data was not always logged and was not always accurate

Read More
news image

Analysis of Hand Sanitizers to Support Label Claims

whitePaper | April 30, 2021

At the height of the first wave of the COVID-19 pandemic, consumers around the world experienced a supply shortage related to alcohol-based hand sanitizer. As new producers entered the market, and existing manufacturers sought to ramp-up production to meet the growing demand, lower grades of ethanol and isopropanol (IPA) started to appear on the market. To ensure the safety and efficacy of hand sanitizer products, it is recommended that manufacturers test their products to ensure appropriate levels of active ingredients, as well as a means of ensuring label-claim accuracy. In this application note, an efficient and simple, “dilute and shoot” method for the analysis of IPA and ethanol in hand sanitizer products is detailed. With a run-time of only 5.36 minutes per sample, this method is ideal for operations requiring fast turnaround times that won’t disrupt the production of their products.

Read More
news image

International Petroleum Corp

whitePaper | October 4, 2022

International Petroleum Corp. Strongly Positioned to Create Stakeholder Value

Read More
news image

Foil Fluid Flow Frustrations

whitePaper | December 9, 2022

The International Society of Automation (ISA) working group responsible for ISA TR 96.05.01 2008 edition on partial stroke testing of automated valves published an update to the original technical report.

Read More

Spotlight

Zafgen, Inc.

Zafgen is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. The company has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and other rare and serious forms of obesity. Zafgen is well-capitalized and has assembled a team accomplished in bringing therapies to patients affected by metabolic disease.

Events